Alexian Brothers Center for Psychiatric Research

Hoffman Estates, Illinois 60194

0 studies enrolling now · 26 studies all time

What they study most

Acute Mania, Adjunctive Treatment of Major Depressive Disorder, Attention Deficit Hyperactivity Disorder, Autism, Bipolar Disorder, Bipolar I Disorder, Cognitive Impairment Associated With Schizophrenia, Depression, Depressive Disorder, Major, Generalized Anxiety Disorder, Generalized Tonic Clonic Seizures, Insomnia

Studies at this site

• SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study — Stopped early
• SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder — Completed
• A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics — Completed
• A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures. — Completed
• Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD) — Stopped early
• Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD) — Completed
• Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD) — Stopped early
• A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder. — Completed
• A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder — Stopped early
• Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD) — Stopped early
• Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder — Completed
• A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder — Completed
• A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder — Completed
• A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02) — Completed
• Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY) — Completed
• Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder — Completed
• A Trial of CM-AT in Children With Autism- Open Label Extension Study — Completed
• Safety and Efficacy of Cariprazine in Patients With Schizophrenia — Completed
• An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia — Completed
• A Trial of CM-AT in Children With Autism — Completed
• A Study of Intermittent Doses of CERC-301 in MDD — Completed
• A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features — Stopped early
• An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia — Stopped early
• Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects — Completed
• Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia — Completed
• Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia — Status unconfirmed